Memantina Farmoz

Memantine Hydrochloride, the active ingredient in Memantina Farmoz, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is used in the management of neurodegenerative disorders, targeting the glutamatergic pathway in Alzheimer’s disease.

- Moderate to severe Alzheimer’s disease: improves cognition, daily functioning and overall clinical status. - Mild‑to‑moderate Alzheimer’s disease (as add‑on therapy): may enhance benefits when combined with a cholinesterase inhibitor. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression in some patients.

Memantina Farmoz may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements, may require dietary adjustment. - Fatigue: feeling of tiredness or reduced energy. - Hypertension: occasional increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare but may occur, particularly in patients with a seizure history. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing heart disease. - Suicidal ideation: new or worsening thoughts of self‑harm.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: assess kidney function and consider dose adjustment. - History of seizures: monitor closely for any seizure activity. - Cardiovascular disease: observe blood pressure and heart rhythm regularly. - Concomitant NMDA antagonists: avoid combined use to reduce neuropsychiatric risk. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Farmoz can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can exacerbate central nervous system effects. - Other NMDA antagonists: heightened risk of severe neuropsychiatric reactions.

Moderate Interactions (Monitor Closely): - Antihypertensives: memantine may potentiate blood‑pressure‑lowering effects. - CNS depressants (e.g., benzodiazepines): increased dizziness or sedation. - Diuretics: may alter renal clearance of memantine, requiring dose review.